Envonalkib

• CAT Number: I045110
• CAS Number: 1621519-26-3
• Molecular Formula: C24H26Cl2FN5O2
• Molecular Weight: 506.40
• Purity: ≥95%
• Synonyms: 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-methoxy-6-[(2S)-2-methylpiperazin-1-yl]pyridin-3-yl]pyridin-2-amine
• InChI: InChI=1S/C24H26Cl2FN5O2/c1-13-10-29-6-7-32(13)21-9-19(33-3)16(12-30-21)15-8-20(24(28)31-11-15)34-14(2)22-17(25)4-5-18(27)23(22)26/h4-5,8-9,11-14,29H,6-7,10H2,1-3H3,(H2,28,31)/t13-,14+/m0/s1
• InChIKey: BVGDAZBTIVRTGO-UONOGXRCSA-N
• SMILES: C[C@H]1CNCCN1C2=NC=C(C(=C2)OC)C3=CC(=C(N=C3)N)O[C@H](C)C4=C(C=CC(=C4Cl)F)Cl

Envonalkib（Cat No.:I045110）is a next-generation, oral anaplastic lymphoma kinase (ALK) inhibitor developed for the treatment of ALK-positive non-small cell lung cancer (NSCLC). It selectively targets ALK fusion proteins, blocking downstream signaling pathways that drive tumor growth and survival. Envonalkib is designed to overcome resistance mutations associated with earlier ALK inhibitors and demonstrates strong central nervous system (CNS) penetration, making it effective against brain metastases. It offers improved potency and safety, with promising clinical activity in both treatment-naïve and resistant patients. Supplied for research in targeted oncology and kinase inhibitor development.